Spoken Alpha
FATE THERAPEUTICS INC
Fate Therapeutics designs off-the-shelf cellular immunotherapies using engineered induced pluripotent stem cells (iPSCs) to create CAR T-cell and NK cell product candidates for treating autoimmune diseases and solid tumors.
FATE THERAPEUTICS INC is a Healthcare company operating in Biotechnology with a $276.8M market cap.
FATE beat consensus EPS by 0.1% in Q2 FY2026, reported Aug 12, 2026.
13 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for FATE.
$ curl https://api.spokenalpha.com/v1/companies/FATEFAQ
Spoken Alpha indexes FATE's earnings call transcripts at https://spokenalpha.com/companies/FATE. Each call links to attributed speakers and parsed analyst Q&A.
FATE THERAPEUTICS INC (FATE) held its most recent earnings call on 2024-05-09, covering fiscal Q1 2024.
FATE THERAPEUTICS INC (FATE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.25 | $-0.28 | +10.7% | $2.1M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.26 | $-0.28 | +7.1% | $1.3M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.27 | $-0.27 | 0.0% | $1.4M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.27 | $-0.28 | +3.6% | $1.7M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.29 | $-0.34 | +14.7% | $1.9M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.32 | $-0.38 | +15.8% | $1.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $-0.44 | $-0.42 | -3.8% | $1.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.40 | $-0.41 | +2.4% | $3.1M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.33 | $-0.45 | +26.7% | $6.8M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.47 | $-0.45 | -4.4% | $1.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-25 | $-0.45 | $-0.52 | +13.5% | $1.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.46 | $-0.56 | +17.9% | $1.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.54 | $-0.58 | +6.9% | $933.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.19 | $-0.62 | +69.3% | $59.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.58 | $-0.86 | +32.6% | $44.4M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.86 | $-0.87 | +1.1% | $15.0M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.78 | $-0.81 | +3.7% | $18.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.68 | $-0.74 | +8.1% | $18.4M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.72 | $-0.67 | -7.5% | $17.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.45 | $-0.55 | +18.2% | $14.2M | — | — | EODHD |
Source: EODHD. FATE reported actuals as published; sparse fields render as —.